Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma has reported advancements in their pivotal Phase 3 study of Namodenoson for treating advanced liver cancer, with increased recruiting centers and ongoing compassionate use programs. Namodenoson, which targets the A3 adenosine receptor, has previously shown promising results in Phase 2 studies, including prolonged survival and tumor clearance in patients. The company highlights the significant global health impact of hepatocellular carcinoma and the potential market growth for treatments, as Namodenoson continues through clinical trials with FDA Fast Track and Orphan Drug statuses.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
